Study Type
Interventional - Drug
REMIT-iDegLira is a multicentre, open-label, randomized controlled trial in patients with recently-diagnosed type 2 diabetes (T2DM).
Participants will be randomized to two treatment groups:
(a) A 16-week period of lifestyle coaching support, metformin and a once-daily injection of IDegLira, and;
(b) Standard diabetes therapy, and followed for a total of 68 weeks (1 year and 4 months).
In all participants with HbA1C less than 7.3% at the 16-week visit, glucose-lowering medications will be discontinued and participants will be encouraged to continue with lifestyle modifications and regular glucose monitoring.
Participants with HbA1C greater than or equal to 7.3% at this visit, or whose HbA1C is greater than or equal to 7.0% at or after the 28 week visit, will receive standard glycemic management.
Primary outcome:
Drug-free diabetes remission defined as a HbA1C less than 6.5% without use of glucose-lowering agents for at least 12 weeks.
Interventional - Drug
Multicentre, open-label RCT
1
8
159
2019 - 2023
PHRI
Back To Top